Overview

Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Status:
RECRUITING

Trial end date:
2028-11-01

Target enrollment:

Participant gender:

Summary

This randomized, open-label study aim to compare the efficacy and safety of rituximab combining anti-CD38 monoclonal antibody with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital, China

Treatments:

Rituximab